← All trials
NCT04941196
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 16, 2020
- Primary completion
- Oct 26, 2020
- Completion date
- Nov 25, 2020
- First posted
- Jun 28, 2021
- Last posted
- Jun 28, 2021
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of KarachiLead sponsor
- University of KarachiReponsible party - principal investigator
- University of KarachiOverall official - principal investigator
- PharmEvo Pvt LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.